The purpose of this study is to evaluate whether 30 mg of pioglitazone administered once daily for up to 28 days to healthy overweight and obese subjects will lead to a significant change in insulin sensitivity, measured in the setting of a hyperinsulinemic euglycemic clamp

Inclusion Criteria:

• Subject has a BMI of greater than 28 kg/m^2 and less than or equal to 38 kg/m^2
• Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months
• Subject is willing to avoid major dietary changes for the duration of the study

Exclusion Criteria:

• Subject has history of diabetes (Type 1, Type 2 or steroid-induced)
• Subject has a history of hypersensitivity to pioglitazone or other thiazolidinediones
• Subject has a history of liver disease, other than non-alcoholic fatty liver disease or non-alcoholic steatohepatitis
• Subject has a history of congestive heart failure
• Subject has a active or past history of atherosclerotic heart disease, heart failure, osteoporosis, osteopenia, recurrent bone fractures, or anemia
• Subject has a history of stroke, chronic seizures, or major neurological disorder
• Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological or renal abnormalities or diseases
• Subject has a history of neoplastic disease within the past 5 years